Company Overview
Inventiva S.A. operates as a clinical-stage biopharmaceutical entity dedicated to developing oral small molecule therapies designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and other diseases across France and international markets. The company is positioned within the broader Healthcare sector, specifically functioning in the Biotechnology industry, where its focus on therapeutic development distinguishes it from traditional pharmaceutical manufacturers that rely on established pipelines. Inventiva S.A. maintains a market capitalization of $1.25B, generates annual revenue of $16.97M, and employs a workforce of 84 individuals to advance its research and development objectives. These valuation and revenue figures indicate that the company holds a significant market presence relative to its current financial output, reflecting the high capital intensity and early-stage nature typical of biotechnology firms focused on novel asset development like Lanifibranor.
Financial Health
The company reported a revenue of $16.97M over the trailing twelve months, yet it recorded a net income of $-311,064,992 and an EBITDA of $-95,789,000, revealing a substantial disparity between top-line sales and bottom-line profitability driven by significant operational expenses. This wide gap between revenue and net income highlights a cost structure heavily weighted toward research, development, and general administrative costs common in clinical-stage ventures where product revenue has not yet offset burn rates. Free cash flow stands at $-77,385,752, indicating that the company is currently burning cash, which limits immediate financial flexibility and necessitates reliance on existing capital reserves or external financing to sustain operations. The gross margin is reported at 95.2%, suggesting highly efficient production or service delivery relative to the cost of goods sold, while the operating margin of -991.9% and profit margin of 0.0% demonstrate severe operating losses relative to sales, typical for companies scaling clinical trials before commercialization. On the balance sheet, Inventiva S.A. holds $122.51M in cash against $132.80M in debt, resulting in a debt-to-equity ratio that is listed as N/A due to the absence of positive shareholder equity in the calculation. The current ratio of 2.96 suggests a conservative short-term liquidity position, indicating that the company possesses nearly three times the current assets required to cover its current liabilities without immediate distress. Return on Equity is listed as N/A because the company lacks positive retained earnings, while the Return on Assets stands at -56.8%, signaling that asset utilization is currently generating negative returns on the capital base deployed by management.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, whereas the forward P/E is calculated at -5.09, implying that market expectations do not yet anticipate positive earnings realization in the near term to justify a traditional price-to-earnings multiple. The price-to-book ratio is reported at -81.04, a metric that is negative because the company's book value per share is below zero, indicating that the market is pricing the stock based on future potential rather than current tangible asset value. The price-to-sales ratio stands at 73.66, and the EV/EBITDA is -8.85, suggesting that valuation models relying on profitability metrics are skewed by current losses, while the high multiple on sales reflects investor pricing of the company's clinical pipeline and potential future revenue streams. Regarding trading range, the 52-week high is $7.98 and the 52-week low is $2.70; without a specific current price provided in the available facts, the stock's position relative to this range cannot be precisely quantified, though the wide spread indicates high volatility. The beta value is 0.92, which means the stock's price volatility is slightly lower than the broader market average, moving in tandem with general market fluctuations but with a margin of stability relative to high-beta biotechnology peers.
Growth & Income
Inventiva S.A. achieved a revenue growth rate of 105.2% year-over-year, while the earnings growth rate is listed as N/A due to the company's continued net losses, indicating that top-line expansion is outpacing any potential path to profitability in the current fiscal period. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash flow is being reinvested into research, development, and clinical trial activities rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage biopharmaceutical companies that prioritize asset growth and pipeline advancement over immediate income generation for investors. The overall growth and income profile of Inventiva S.A. is characterized by rapid revenue expansion and a complete absence of dividend income, reflecting a high-risk, high-potential investment vehicle focused entirely on future clinical milestones and commercialization success.